Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1440 participants.

Also called NCT06010628

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06010628
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06010628. Randomized; single masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2029-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
Condition
Stroke, Ischemic
Intervention (Drug)
Tenecteplase
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct06010628
Content hash
127a181010bdd25ec61a1ad805b7c978327b91150998b6f870aa8ac2ccfb6c8c